In this study, ACC demonstrated a higher frequency of gene aberrations such as BRCA2 (16.3%) and ATM (8.8%), which may benefit from platinum-based therapy and PARP inhibitors [25, 26]. Here, BRCA2 is linked to adrenal cortex carcinoma.